Immuno-Oncology

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dana Monroe from San Francisco Oncology Associates Discusses Ipilimumab's Side Effects

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies

Immunotherapies again made headlines in oncology last month

The federal agency that determines Medicare reimbursements this week proposed to fully cover the cost of Provenge

Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks

James P. Allison has never hesitated to buck the system

A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.

The fields of oncology and biotechnology are entering a period of rapid growth and transformation. It is an exciting time for physicians, researchers, and allied healthcare professionals. We are honored to be apart of the process.

This month's Fed Focus highlights the CDC's HPV vaccine recommendations as well as changes in Medicare coverage of ESAs for cancer-related anemia. Our reports from

With this and every issue of Oncology & Biotech News, we seek to provide clinicians with practical news with a global perspective. As we move forward, it is our goal to provide more information from markets outside the United States. Your input is essential to developing this publication into a useful tool for you in your daily practice.

Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.

Provenge becomes the first immunotherapy vaccine against cancer to win FDA approval